Wednesday
SESSION 31: NATURAL HISTORY, MEDICAL TREATMENTS AND ANTI-ATHEROSCLEROTIC MEDICATIONS
SESSION 31 SCHEDULE
6:45 AM - 6:50 AM Is Metabolic Syndrome A Marker Of Adverse Outcomes After Vascular Procedures: What Can Be Done To Improve The Situation
  Presenter(s):Alan Dardik, MD, PhD  
  View Slides in PDF      
6:51 AM - 6:56 AM Cilostazol (Pletal) Is An Underutilized Medication In Vascular Patients: It Can Promote Patency And Decrease Amputations After Arterial Revascularizations: What Is Optimal Timing And Dosing For Its Use
  Presenter(s):Todd R. Vogel, MD, MPH  
  View Slides in PDF      
6:57 AM - 7:03 AM How Should Beta Blockers Be Used In Vascular Patients Undergoing Procedures: Use And Overuse Can Harm Patients And Their Use Should Not Be A Quality Metric
  Presenter(s):Michael C. Stoner, MD  
  View Slides in PDF      
7:04 AM - 7:09 AM How Do Patient Risk Factors And Antiplatelet Medications Influence Myocardial Ischemia And Infarction In Patients Undergoing Open Arterial Operations: What Can Be Done To Decrease These Adverse Events
  Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC   
  View Slides in PDF      
7:10 AM - 7:15 AM Smoking, Cholesterol, Obesity And BP: The Big 4 Modifiable Causes Of Vascular Disease: Fix Them And Live Forever: What Is Optimal Statin Usage
  Presenter(s):Richard Bulbulia, MA, MD, FRCS  
  View Slides in PDF      
7:16 AM - 7:21 AM What Is Happening With The AHA Cholesterol Guidelines: Should We Measure Serum Cholesterol: How Low Should The LDL Be Pushed To And Can It Get There
  Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC   
  View Slides in PDF      
7:22 AM - 7:27 AM Status Of Cholesterol Lowering Drug Zetia (Ezetimbe) And Its Combination With Statins (Vytorin): Do They Help To Prevent Cardiovascular Events More Than Statins Alone: Who Should Be On Them: The IMPROVE –IT Trial
  Presenter(s):Don Poldermans, MD  
  View Slides in PDF      
7:28 AM - 7:33 AM Status Of The New Cholesterol Lowering Drugs: The PCSK 9 Inhibitors (Evolucumab [Amgen] And Alirocumab [Sanofi]): Do They Decrease Cardiovascular Events: How Are They Given; What Are Their Downsides; What Will Their Role Be And When Will They Be Available
  Presenter(s):Ron Waksman, MD  
  View Slides in PDF      
7:34 AM - 7:39 AM Statins And Dual Antiplatelet Drugs Reduce Amputations: What Is The Evidence
  Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR  
  View Slides in PDF      
7:40 AM - 7:48 AM Panel Discussion
END OF SESSION 31
previous next